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Abstract
The actomyosin motor complex of the glideosome provides the force needed by apicomplexan parasites such as
Toxoplasma gondii (Tg) and Plasmodium falciparum (Pf) to invade their host cells and for gliding motility of their motile
forms. Glideosome Associated Protein 45 (PfGAP45) is an essential component of the glideosome complex as it facilitates
anchoring and effective functioning of the motor. Dissection of events that regulate PfGAP45 may provide insights into how
the motor and the glideosome operate. We found that PfGAP45 is phosphorylated in response to Phospholipase C (PLC)
and calcium signaling. It is phosphorylated by P. falciparum kinases Protein Kinase B (PfPKB) and Calcium Dependent Protein
Kinase 1 (PfCDPK1), which are calcium dependent enzymes, at S89, S103 and S149. The Phospholipase C pathway influenced
the phosphorylation of S103 and S149. The phosphorylation of PfGAP45 at these sites is differentially regulated during
parasite development. The localization of PfGAP45 and its association may be independent of the phosphorylation of these
sites. PfGAP45 regulation in response to calcium fits in well with the previously described role of calcium in host cell
invasion by malaria parasite.
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Introduction
Malaria is one of the major causes of morbidity and mortality in
the developing world claiming as many as 1 million lives per year
[1]. Plasmodium falciparum causes the most severe form of the
disease. It follows a complex life cycle involving different stages of
development that require human and mosquito hosts.
Invasion of an erythrocyte by a merozoite is initiated by specific
ligand receptor interactions between them [2]. Following this, the
merozoite reorients and juxtaposes its apical end with the Red
Blood Corpuscle (RBC) membrane resulting in the formation of
an irreversible tight junction. The parasite then actively propels
itself into the RBC membrane and subsequently is enclosed inside
the parasitophorous vacuole. The motor complex which is
engaged in the invasion of merozoites is known as the glideosome
and was initially described in Toxoplasma gondii [3,4]. It comprises
of a heterotetrameric complex that is anchored in the Inner
Membrane Complex (IMC) of the zoite pellicle. In P. falciparum,i t
has been demonstrated to comprise of a class XIV Myosin
(PfMyoA) and its associated light chain Myosin Tail Interacting
Protein (PfMTIP) [5–8]. PfGAP45 is a 204 amino acid protein,
which is highly conserved. It is predicted to consist of two separate
domains, an N terminal coiled coil domain and a C terminal
globular domain. Glideosome Associated Protein 50 (PfGAP50) is
a transmembrane protein that anchors the glideosome in the IMC
[8,9]. Gliding motility is achieved by the controlled polymerization
of actin filaments between the Plasma Membrane (PM) and the
IMC [10]. The actin-myosin motor is in turn connected to
extracellular ligands that interact with receptors on the erythrocyte
membrane. The forward motion of the parasite is caused by
repetitive binding and release of actin filaments by myosin. Post
translational modifications have been reported to occur on
different players of the glideosome complex. PfMTIP was shown
to be phosphorylated in the parasite and is an in vitro substrate for
PfCDPK1 [7,11]. TgGAP50 requires glycosylation at three
different sites in order to be targeted to the IMC [12]. TgGAP45
has been implicated in the recruitment of the motor complex as
well as in the maintenance of pellicle cohesion. The N terminus of
TgGAP45 has putative acyl modification sites and mutational
analysis indicated that these may be essential for temporally
regulating the insertion of the protein into the IMC. In addition,
the palmitoylation of cysteines at the C-terminus of TgGAP45 was
implicated in anchoring it to the outer leaflet of the IMC [13].
PfGAP45 is also myristoylated and palmitoylated and these
modifications may be essential for its membrane targeting [14].
GAP45 undergoes phosphorylation in both Toxoplasma and
Plasmodium [7,15–17].
Given the importance of PfGAP45 in motor function and
invasion, it is important to understand cellular processes that may
regulate its phosphorylation. Calcium release mediated by PLC
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Receptor (cADPR-RyR) pathways [20] has been implicated in
erythrocyte invasion by the parasite. Our studies demonstrate that
the phosphorylation of PfGAP45 is regulated by calcium and is
controlled by PLC. We have identified that PfGAP45 is
phosphorylated at S103 and S149 in response to PLC mediated
calcium release and phosphorylation of PfGAP45 at these sites is
developmentally regulated. While PfPKB can phosphorylate
PfGAP45 on S103, PfCDPK1 can also phosphorylate it on S89
and S149. Both PfPKB and PfCDPK1 are regulated by calcium;
while calcium directly stimulates PfCDPK1 activity [7], it can
combine with calmodulin to activate PfPKB [21].
Materials and Methods
Parasite culture and transfections
For all experiments, the 3D7 strain of P. falciparum was used,
which was cultured in complete RPMI 1640 medium with 5%
albumax (Invitrogen) at 37uC as described previously [22].
Parasites were synchronized by sorbitol treatment [22]. For
generating transgenic lines expressing PfGAP45 fused with Green
Fluorescent Protein (GFP) at its C-terminus, PfGAP45 and its
mutants were cloned in pARL vector [23] containing the GFP
gene and a human Dihydrofolate Reductase (DHFR) gene which
confers resistance to WR99210. The following primers were used
Forward: 59GGGGTACCGGATGGGAAATAAATGTTCA39,
Reverse: 59 CCG CCTAGGATTAGCTCAATAAAGGTG 39
to facilitate cloning in KpnI/AvrII sites of the pARL-GFP vector.
The transfection of plasmid DNA in the parasite was done by
electroporation [24] and selected with WR99210 [25].
Recombinant protein expression and generation of
antisera
GST-DPfPKB [26], 6xHis-GAP45 and 6xHis-MTIP [17] were
expressed and purified as previously described. Mutations in
PfGAP45 were made using either Quickchange
TM Site-Directed
Mutagenesis Kit (Stratagene) or by overlapping PCR. PfCDPK1
was cloned using forward primer 59CGTGGATC-
CATGGGGTGTTCACAAAGTTCAAACG 39 and reverse
primer 59CCGCTCGAGTTGAAGATTTATTATCACAAA 39
in pET28a vector. The 6x-His tagged protein was expressed in
BL21 RIL (DE3) E.coli cells by using 1 mM Isopropyl-1-thio-b-D-
Galactopyranoside (IPTG) at 18uC for 16 hours. Cells were
resuspended in cold resuspension buffer (50 mM PO4 buffer,
150 mM NaCl, 0.1% Nonidet-P40, 1 mM DTT and 10 mg/ml
pepstatin, 10 mg/ml leupeptin, 1 mM benzamidine, 1 mM PMSF
at pH 7.4), sonicated on ice and centrifuged at 12000 g for
30 minutes at 4uC. The cell lysate was incubated with equilibrated
Ni-NTA agarose beads (Invitrogen) at 4uC for 4 hours. Following
binding, the resin was washed with resuspension buffer and the
protein was eluted using 50–300 mM of imidazole. The eluted
fractions were dialyzed against 50 mM sodium phosphate buffer
pH 7.5, 10% glycerol and 1 mM DTT.
Generation of antisera and phosphorylation-site specific
antibodies
Antisera were raised against recombinant PfGAP45 and
PfMTIP, which has been described previously [17]. The
antibodies against PfGAP45 phosphorylated at S103 or S149
were custom generated by Antagene. Inc. (USA). For this purpose,
peptides with the following sequence were used: pS103: DLERSN-
pS-DIYSES; pS149: EPAHEE-pS-IYFTY. The phosphorylated
peptides were used to immunize rabbits over a 10 week schedule.
Antisera were collected and antibody titers were determined by
performing ELISA against the phosphorylated and the unmodified
peptides. The antisera were enriched in the anti phosphopeptide
antibodies by using a phosphopeptide affinity column and were
further purified by passing through an unmodified peptide column
by affinity depletion.
Kinase assays
Using recombinant PfGAP45 or its mutants and DPfPKB or
PfCDPK1 as kinase, activity assays were carried out in a reaction
Figure 1. PfGAP45 phosphorylation is regulated via the PLC pathway in the parasite. A. [
32P] orthophosphoric acid was used to
metabolically label synchronized parasites treated with 10 mM U73122 or its inactive analogue U73343, 40 mM 8-Br-cADP-ribose or 10 mM Dantrolene.
Immunoprecipitation was carried out using anti-GAP45 antibody and the IPs were electrophoresed and analyzed by phosphorimaging. Lower panel,
western blot for PfGAP45 was performed on the protein lysate used in the above immunoprecipitation experiments. B. The phosphate incorporation
in PfGAP45 in experiments like the one described in panel A was assessed by either densitometric quantitation or by cerenkov counting of bands
corresponding to
32P-labelled PfGAP45, which was normalized to total PfGAP45 levels. % phosphorylation of PfGAP45 in response to various
treatments is provided, the phoshorylation of DMSO treated control was taken as 100%. The mean from the densitometry measurements (black bars)
for four independent experiments is shown. For two of these experiments, cerenkov counting of labeled PfGAP45 band was also performed and the
average is presented as grey bars, error bars represent standard error.
doi:10.1371/journal.pone.0035855.g001
Regulation of PfGAP45 Phosphorylation
PLoS ONE | www.plosone.org 2 April 2012 | Volume 7 | Issue 4 | e35855buffer containing 50 mM Tris pH 7.5, 10 mM magnesium
chloride, 1 mM dithiothreitol and 100 mM Adenosine triphos-
phate (ATP) (15 mCi/reaction) For reactions that were carried out
using PfCDPK1 as enzyme 0.1 mM CaCl2 was added additionally
to the reaction mix. Reactions were carried out at 30uC for
40 minutes and stopped by boiling in SDS-PAGE loading buffer.
The reaction mixture was electrophoresed on SDS-PAGE and
phosphorylation of proteins was detected by phosphorimaging
using a Fuji FLA5000 scanner. For inhibition assays, A443654 was
incubated with the enzyme for 10 minutes prior to the addition of
the substrate and radiolabelled ATP.
Phosphopeptide mapping
The kinase assays were carried out as described above and the
reaction mixture was transferred to nitrocellulose membrane
following SDS-PAGE. The radiolabelled bands corresponding to
phosphorylated PfGAP45 or its mutants were excised from the
membrane and washed before blocking with 0.5% polyvinylpyr-
rolidine (prepared in 100 mM acetic acid) for 30 minutes at 37uC
with shaking. After washing with 50 mM ammonium bicarbonate
pH 8.0, overnight digestions were carried out with trypsin gold
(Promega). The supernatants from each reaction were collected
and dried using a speedvac at 45uC. The phosphopeptides were
resupended in 10 ml 2.5% formic acid, 7.8% glacial acetic acid
pH 1.9 and counts per minute (cpm) in each sample were
determined by scintillation counting. Equal cpm from each sample
were loaded onto PEI cellulose TLC plates (Merck). Phosphopep-
tides were separated in the first dimension by electrophoresis at
pH 1.9 for 50 minutes at 1000 V using Hunter thin layer peptide
mapping system (CBS Scientific. Inc.). Separation in the second
dimension was carried out by chromatography in 7.5% glacial
acetic acid, 25% pyridine, 37.5% n-butanol. The radiolabelled
peptides were detected by phosphorimaging of the TLC plates
[27].
Figure 2. PfGAP45 is phosphorylated by PfPKB and PfCDPK1. A,aIn vitro kinase assay was performed using recombinant DPfPKB to
phosphorylate an equal amount of PfGAP45 or its S103A mutant. The phosphorimage shows phosphate incorporation in PfGAP45. b,
Phosphopeptide mapping was performed on DPfPKB phosphorylated PfGAP45 or the S103A mutant. B. a, PfCDPK1 kinase assay was performed
using an equal amount of recombinant PfGAP45 or its S89A, S103A and S149A mutants. b, Phosphopeptide mapping was carried out on PfGAP45 or
indicated mutants which were phosphorylated with PfCDPK1. Five major spots representing labeled phosphopeptides in the case of WT PfGAP45 are
encircled and are numbered 1–5. Broken circles are used to indicate the lack or reduced labeling of peptides in the case of mutants. Arrowhead
indicates the additional phosphopeptide in S149A mutant. The origin where the peptides were spotted is marked as ‘‘O’’. C. PfGAP45 is
phosphorylated at least three major sites. While S89 and S149 can be phosphorylated by PfCDPK1 in vitro, PfPKB as well as PfCDPK1 phosphorylate
S103. S89 and S103 are present in the coiled-coil region of the kinase whereas S149 is in the globular domain of PfGAP45.
doi:10.1371/journal.pone.0035855.g002
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Parasite-infected erythrocytes after various treatments were
lysed in 0.05% saponin at 4uC for 10 minutes. The released
parasites were washed in cold Phosphate Buffered Saline (PBS)
and resuspended in complete lysis buffer containing 100 mM Tris
pH 7.5, 100 mM sodium chloride, 5 mM EDTA, 1% Triton X-
100, 100 mM sodium orthovanadate, 20 mM b glycerophosphate,
16protease inhibitor cocktail (Roche) and 10% glycerol. 100 mg
protein lysate was used for immunoprecipitation and incubated
with relevant antibodies at 4uC for 5 hours followed by incubation
with protein A+G sepharose beads (GE Healthcare) for 12 hours.
The beads were washed with cold lysis buffer and resuspended in
50 ml of kinase assay buffer or SDS PAGE loading buffer.
Immunofluorescence assays (IFA)
IFA was performed on either thin blood smears or on parasites
in suspension. For IFAs performed on smears, cold methanol was
used for fixation. The parasites were permeabilized with 0.05%
saponin in PBS followed by washing in PBS and blocked with 3%
bovine serum albumin for 30 minutes at room temperature. The
parasites were incubated with relevant antibodies at 4uC, washed
with PBS and incubated with AlexaFluor 488/594 labelled
secondary antibodies (Invitrogen) at room temperature. Following
washing, vectashield mounting medium containing DAPI was
used. In the case of IFAs on parasite suspensions, 4% para-
formaldehyde and 0.0075% glutaraldehyde in PBS pH 7.4 was
used for fixation and the parasites were permeabilized with 0.1%
Triton 6100 [28]. The stained parasites were visualized using
AxioImager Z1 microscope (Carl Zeiss). Z stacking during image
acquisition and processing of images was done using Axiovision
4.8.2 software. The Z-stacks which best represented the immuno-
localization were used for illustrations in the figures. Adobe
photoshop software was also used for preparing images for figures.
Fractionation of merozoite proteins
Segmentor/schizont stage, which contained more than ,18
merozites, was centrifuged at ,300 g for 5 minutes to separate
erythrocytes from free merozoites. The supernatant containing
merozoites was further centrifuged at 15000 g for 10 minutes to
collect free merozoites. To the merozoite pellet, either PBS, PBS/
1 M sodium chloride, PBS/0.1 M sodium carbonate pH 11.0 or
PBS/0.1% triton X-100 was added and lysed by passing the
suspension through a syringe and freeze thawing in liquid nitrogen
followed by centrifugation at 16000 g for 1 hour at 4uC. The
pellet fraction in all cases was solubilized in 2% SDS [13].
Alkaline phosphatase treatment of lysate
30 mg of segmentor schizont lysate from tightly synchronized
culture was treated with 60 units (2 units/mg protein) alkaline
phosphatase in a 50 ml reaction at 37uC for 2 hours. Reactions
were stopped by boiling in SDS PAGE loading buffer and used for
western blotting.
Metabolic labeling
Tightly synchronized cultures at ,42 h post invasion at ,8%
parasitemia/5% hematocrit were washed with phosphate or
methionine/cysteine deficient RPMI 1640 medium (Hyclone)
supplemented with 5% albumax. Parasites in culture were
incubated with [
32P] orthophosphoric acid (1–2 mCi/ml) [29] or
[
35S] methionine/cysteine (300 mCi/ml) [5,14] till most parasites
Figure 3. PfGAP45 is phosphorylated at S89, S103 and S149 in the parasite. A. Transgenic parasite lines expressing GAP45 or various
mutants fused to GFP were generated (see Materials and Methods). Schizont stage parasite cultures were incubated with [
32P] orthophosphoric acid.
Using anti-GFP antibody, GAP45 or its mutants were immunoprecipitated followed by SDS PAGE and phosphorimaging. Lower Panel, western
blotting was performed on the protein lysates from the above experiment using anti-GFP antibody to assess the levels of PfGAP45-GFP. B. Antisera
were raised against phosphopeptides corresponding to S103 (bottom panel) and S149 (middle panel) (see Experimental procedures, Fig. S1). Using
these and antisera against total PfGAP45 (top panel), western blotting was performed on schizont lysate, which was either left untreated or treated
with alkaline phosphatase. Both phospho-antibodies recognized a band corresponding to PfGAP45 only in the untreated parasites indicating that
S103 and S149 are phosphorylated in the parasite.
doi:10.1371/journal.pone.0035855.g003
Regulation of PfGAP45 Phosphorylation
PLoS ONE | www.plosone.org 4 April 2012 | Volume 7 | Issue 4 | e35855were segmentors. Subsequently, parasite lysates were made and
relevant antibodies were used for immunoprecipitation as de-
scribed above. The immunoprecipitates (IP) were electrophoresed
and labelled proteins were detected using a Fuji FLA5000 scanner
or autoradiography. The phosphate incorporation was quantitated
by performing densitometry using the Image J software.
Results
PfGAP45 is phosphorylated in response to phospholipase
C mediated calcium release
We [17] and others [7] have previously reported that PfGAP45
is phosphorylated in the parasite. However, signaling pathways
involved in its phosphorylation have remained obscure. Since two
calcium dependent kinases, PfPKB [17,21] and PfCDPK1 [7,30],
phosphorylate PfGAP45 in vitro, we first probed if calcium plays
a role in PfGAP45 phosphorylation in the parasite. Parasite
proteins were labeled with
32P followed by immunuprecipitation of
PfGAP45 (Fig. 1, Fig. S4). PfGAP45 was phosphorylated in the
parasite and treatment of parasites with BAPTA-AM, an in-
tracellular calcium chelator, significantly reduced PfGAP45
phosphorylation (Fig. 1, lane 2), which suggested that intracellular
calcium regulates PfGAP45 phosphorylation. In most eukaryotic
cells, calcium release from intracellular stores is triggered by two
major pathways; PLC triggered calcium release involves Inositol
triphosphate (IP3) receptors and cADP-ribose stimulates calcium
release via ryanodine-responsive calcium channels [31]. Although
the IP3 receptor and RyR channels have not been identified in the
parasite, both of these pathways regulate calcium release in the
parasite and in the invasion of host RBCs by the malaria parasite
[17,20]. To assess the role of PLC in PfGAP45 phosphorylation,
parasites were treated with U73122, a PLC inhibitor or its inactive
analogue U73343. While U73122 caused a marked reduction in
PfGAP45 phosphorylation, U73343 was significantly ineffective
indicating that PLC mediated calcium release may promote
PfGAP45 phosphorylation (Fig. 1, lane 3 v/s lane 4). In contrast,
8Br-cADP-ribose or Dantrolene, which were used to explore the
involvement of cADPR-RyR pathway, failed to cause any
significant change in PfGAP45 phosphorylation (Fig. 1, lanes 5
and 6).
Identification of PfPKB and PfCDPK1 phosphorylation
sites on PfGAP45
The finding that PfGAP45 is a target of calcium signaling in the
parasite fits in well with previous studies which indicated that
PfGAP45 can be phosphorylated by two calcium regulated kinases
PfPKB [17] and PfCDPK1 [7] in vitro. Since the identity of the
target phosphorylation sites for these kinases remained unknown,
efforts were made to address this important question. Recombi-
nant PfGAP45 was incubated with a constitutively active PfPKB
mutant, DPfPKB or PfCDPK1 and subjected to mass spectrom-
etry as part of an independent study (Sharma, Jaffe, unpublished
data). Mass spectrometric studies lead to the identification of
phosphopeptides from the kinase assay reactions and suggested
a single putative phosphorylation site (S103) for PfPKB and at least
three sites (S89, S103 and S149) for PfCDPK1. To confirm the
identity of these sites, S to A mutants were generated for these
residues and the mutants were analyzed by phosphopeptide
mapping. PfPKB phosphorylated PfGAP45 at one major site as
indicated by a single labeled spot on the phosphopeptide map
Figure 4. PfGAP45 may be phosphorylated by PfPKB at S103 in the parasite. A. A443654 inhibits PfPKB and not PfCDPK1. In vitro kinase
assays were performed to phosphorylate recombinant PfGAP45 by DPfPKB or PfCDPK1 in the absence (DMSO) or presence of indicated concentration
of A443654. Treatment with A443654 inhibited the activity of PfPKB while PfCDPK1 activity remained almost unaffected. B. A443654 blocks the
phosphorylation of S103 in the parasite. Western blotting was performed using anti-phospho-S103 and anti-phospho-S149 antisera on the lysate of
schizonts that were treated with A443654 (lane 2) or DMSO (lane 1). While almost no change in the phosphorylation levels of S149 was seen,
phosphorylation at S103 was significantly reduced. Lower panel, The densitometric quantitation of pS103-GAP45 and pS149-GAP45 bands was
performed and normalized with respect to GAP45. The % phosphorylation of S103 or S149 in comparison to DMSO (100%) is shown and the mean of
two independent experiments is provided and error bars represent standard error.
doi:10.1371/journal.pone.0035855.g004
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mutation of S103 to alanine (Fig. 2A, b) confirming it to be the
phosphorylation site for PfPKB. In the case of PfCDPK1, at least
five major phosphopeptides were generated on PfGAP45 (Fig. 2B,
b). The kinase assay with mutants S89A, S103A and S149A
revealed a decrease in the phosphorylation of S89 and S103
(Fig. 2B, a). The peptide maps revealed that the labeling of peptide
2 and 1 was abolished upon mutation of S89 and S103 respectively
(Fig. 2B, b), which confirmed these two serines as phosphorylation
sites for PfCDPK1. The mutation of S149A did not reveal a net
decrease in phosphorylation on SDS-PAGE gel (Fig. 2B, a).
Interestingly, the mutation of S149A resulted in slight rearrange-
ment of the map: while a loss in the labeling for peptide 5 and
a decrease for peptide 2 was evident, an additional labeled peptide
emerged (Fig. 2B, b, arrowhead). This observation might explain
no discernable decrease on net phosphorylation of S149A mutant
(Fig. 2B, a). These data also suggested that S149 may be
a phosphorylation site for PfCDPK1 and its phosphorylation
possibly influences the phosphorylation of sites, which need to be
identified. Furthermore, independent experiments using antibo-
dies specific to PfGAP45 phosphorylated at S103 or S149
(described below) confirmed that S103 and S149 can be
phosphorylated by PfCDPK1 in vitro (Fig. S1). Collectively, these
results suggest that S103 can be phosphorylated by both PfPKB
and PfCDPK1 and S89 and S149 are phosphorylated by
PfCDPK1 (Fig. 2C).
S89, S103 and S149 are phosphorylated in the parasite
Having demonstrated that PfGAP45 is phosphorylated at S89,
S103 and S149 by PfCDPK1 and PfPKB in vitro, we investigated if
these sites were phosphorylated in the parasite. To this end,
parasite lines expressing wild type or mutant GAP45 with GFP
fused to its C-terminus were generated. After metabolic labeling of
parasite cultures with
32P, GFP fusion proteins were immunopre-
cipitated. A significant reduction in the phosphorylation of S103A
was observed (Fig. 3A, lane 2), which was even more pronounced
in the case of S89/S103A and S89/S103D double mutants
(Fig. 3A, lanes 5 and 6). In comparison, S149A mutation caused
only a minor decrease, which may have been due to a compen-
satory increase in total phosphorylation by phosphorylation at
additional sites (Fig. 3A, lane 3) as indicated by in vitro experiments
(Fig. 2B).
Phosphorylation site specific antibodies are useful tools to study
site-specific phosphorylation of proteins in vivo. Antibodies against
phosphopeptides corresponding to S103 and S149 were success-
fully generated (Figure S1). The western blot performed on
parasite lysates with these antibodies resulted in a band corre-
sponding to the size of PfGAP45 (Fig. 3B), Treatment of the
parasite lysate with alkaline phosphatase resulted in a loss of
immunoreactivity against these peptides suggesting that these
antibodies specifically recognize PfGAP45 phosphorylated at S103
and S149 and confirmed PfGAP45 phosphorylation at these
residues in the parasite.
Figure 5. Phosphorylation of S103 and S149 on PfGAP45 is temporally regulated. A. Parasites were tightly synchronized and were
harvested at indicated time post-invasion (late trophozoite to segmentor) to prepare protein lysates. Western blotting was carried out using anti-
PfGAP45, anti-phospho S103 and anti-phospho S149 on these lysates. B. The intensity of the bands in the western blots in panel A was quantified by
densitometry, which was performed using Image J software. The ratio of phospho-S103 or phospho-S149 to the total PfGAP45 is indicated in the
graph. Average from two different experiments is provided, the error bars represent standard error. C. Western blotting was performed on protein
lysates from tightly synchronized parasites from the experiment described in panel A using anti-PfPKB and anti-PfCDPK1 antibodies. Actin was used
as the loading control.
doi:10.1371/journal.pone.0035855.g005
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S103 in the parasite
The results of kinase assays described above suggested that both
PfCDPK1 and PfPKB may phosphorylate PfGAP45 at S103. We
made attempts to identify the likely kinase that may phosphorylate
S103 in the parasite. A443654, which was first identified as an
inhibitor of mammalian PKB [32], inhibits PfPKB [17]. Unlike
PfPKB, this inhibitor failed to inhibit PfCDPK1 activity in vitro
suggesting that it is specific to PfPKB (Fig. 4A). When this inhibitor
was added to parasites, a significant decrease in the phosphory-
lation of S103 was observed implicating PfPKB in the phosphor-
ylation of PfGAP45 at S103. Importantly, the phosphorylation
levels of S149, which is not phosphorylated by PfPKB, remained
almost unaltered upon A443654 treatment (Fig. 4B). Based on
these observations, PfPKB emerged as the likely parasite kinase
needed for the phosphorylation of S103.
Phosphorylation of PfGAP45 during parasite
development
Having demonstrated the phosphorylation of PfGAP45 at S103
and S149, we next investigated if the phosphorylation of these sites
is developmentally regulated. To this end, parasite lysates were
prepared from late trophozoites (,33 h post invasion) to late
schizont/segmentor stage and were probed with phospho specific
antibodies. While the phosphorylation of S149 was observed as
early as ,39 h, when the parasites were late trophozoites or early
schizonts, phosphorylation of S103 was undetectable. In contrast,
S103 phosphorylation was seen mainly at 42–45 h in mature
schizonts (Fig. 5A, B). To correlate with S103 and S149
phosphorylation, the expression profiles of PfCDPK1 and PfPKB
the two candidate kinases for these sites, were also determined.
While PfCDPK1 was expressed early in parasite development,
PfPKB was expressed mainly in the mature schizonts as also
reported earlier (Fig. 5C) [26]. The expression levels of PfCDPK1
and PfPKB correlate well with the phosphorylation status of S103
and S149, respectively. These data strongly suggest that the
phosphorylation of S103 and S149 and the expression of the two
candidate kinases for these sites are differentially regulated during
parasite development.
Figure 6. Phosphorylation at both S103 and S149 is regulated via the PLC pathway. A. Schizonts were treated with 40 mM BAPTA-AM,
10 mM U73122 or its analogue U73343, 5 mM Ionomycin alone or in combination with 10 mM U73122, 40 mM 8Br cADP-ribose and 10 mM Dantrolene
followed by Western blotting using anti-phospho S103 and anti-phospho S149 antisera. The phosphorylation at both S103 and S149 seems to be
regulated via the PLC pathway. B. Densitometric quantitation of indicated bands from the experiments described in panel A. The % phosphorylation
of S103 (black) or S149 (grey) in comparison to DMSO (100%) is provided. The mean of two independent experiments is shown and error bars
represent standard error
doi:10.1371/journal.pone.0035855.g006
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PLoS ONE | www.plosone.org 7 April 2012 | Volume 7 | Issue 4 | e35855Figure 7. PfGAP45 phosphorylation mutants co-localize with the IMC marker PfMTIP. Immunofluorescence assays were performed using
anti-GFP (red) and anti-PfMTIP (green) antibodies on parasite lines over-expressing PfGAP45-GFP or its variants. Both WT and mutant PfGAP45 show
co-localization with PfMTIP around the periphery of merozoites in mature schizonts. Similar results were obtained upon live imaging of GFP
fluorescence in parasites (Fig. S3).
doi:10.1371/journal.pone.0035855.g007
Figure 8. The role of phosphorylation on membrane association of PfGAP45. The solubility of PfGAP45-GFP or its mutants and endogenous
PfGAP45 was assessed by performing extractions in PBS, PBS/1 M NaCl, PBS/0.1 M Na2CO3 pH 11.0 or PBS/0.1% Triton6100. The supernatant (S) and
the pellet (P) fractions were subjected to western blotting using anti GFP and anti GAP45 antibody (bottom panel) as indicated.
doi:10.1371/journal.pone.0035855.g008
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The results described in Figure 1 indicate that PfGAP45 may be
phosphorylated in response to PLC mediated calcium release. The
phospho S103 and S149 antibodies were used to study if the
phosphorylation at these sites was influenced by PLC-calcium
signaling. The treatment with BAPTA-AM almost completely
prevented the phosphorylation at S103 and S149, thereby
providing strong evidence for the involvement of calcium
dependent kinases in the phosphorylation of these residues. The
PLC inhibitor, U73122, significantly reduced the phosphorylation
of PfGAP45 at both S103 and S149 (Fig. 6, lane 3). Moreover,
when a calcium ionophore ionomycin, which facilitates intracel-
lular calcium release, was used in combination with U73122,
a significant recovery in phosphorylation of both these sites was
observed (Fig. 6, lane 5 v/s lane 3). These data suggested that PLC
mediated calcium release may regulate kinases like PfPKB [21]
and PfCDPK1 (Sharma and co-workers, unpublished results),
which in turn may phosphorylate S103 and S149 of PfGAP45. In
contrast, no significant change in the phosphorylation of S103 or
S149 was caused by 8-Br-cADP-ribose or Dantrolene (Fig. 6, lane
7 and 8).
Phosphorylation of S89, S103 and S149 may not be
involved in PfGAP45 targeting and glideosome assembly
formation
We investigated the role of phosphorylation in PfGAP45 cellular
localization and association with the glideosome assembly. GAP45
has N-terminal myristoylation and palmitoylation signals which
are necessary for its membrane targeting [13,14]. mCherry or
GFP fused to PfGAP45 C-terminal is targeted to the IMC
[Gilberger and co-workers, manuscript under revision, [5]].
Therefore, parasite lines over expressing GAP45 with GFP fused
to its C-terminus were generated. Immunofluorescence assays
suggested that GAP45-GFP was targeted to the expected
localization at the IMC as indicated by co-localization with
endogenous PfGAP45 (Fig. S2, Fig. S3) as well as IMC protein
PfMTIP (Fig. 7). The alanine or phosphate mimicking aspartic
acid mutation of phosphorylation sites S89, S103 and S149 did not
appear to cause significant changes to the co-localization with
PfMTIP (Fig. 7, Fig. 3B) in late schizonts/merozoites. Cellular
fractionation experiments were performed to further validate the
membrane targeting of PfGAP45 and mutants in merozoites. The
endogenous PfGAP45 was almost completely insoluble in PBS as
well as high salt buffer. While it was readily soluble in Triton X-
100, its solubility was extremely low in sodium carbonate pH 11.0
(Fig. 8). The mutation of any of the phosphorylation sites did not
cause a discernable change in its solubility, therefore phosphor-
ylation at the mutated sites may not play a direct role in
membrane targeting of PfGAP45. In addition,
35S-labeling-
immunoprecipitation and co-immunoprecipitation experiments
suggested no significant change in the interaction of GAP45-
GFP with other glideosome proteins upon mutation of S89, S103
and S149 (Fig. S4). Therefore, the phosphorylation of S89, S103
and S149 may not be involved directly in glideosome complex
formation. It is indeed possible that the phosphorylation of
PfGAP45 at additional sites is needed for its function.
Discussion
It is clear that the assembly of glideosome complex proteins is
pivotal for the targeting and functioning of the actomyosin motor
in apicomplexans. Several studies performed on Plasmodium [5,6,8]
and Toxoplasma [3] have indicated that the motor complex
comprises of at least four major proteins MyoA, MLC1/MTIP,
GAP45 and GAP50 with additional proteins associated with the
complex [13,33]. Although recent work suggests that GAP45 and
MTIP may be phosphorylated [7,16,17], there is little information
about what cellular events regulate their phosphorylation. Given
the role of calcium and the importance of the motor in invasion,
we dissected calcium signaling events that may control PfGAP45
phosphorylation. U73122 a pharmacological inhibitor of PLC
which is also effective against malarial PLC [(Pushkar Sharma,
Guru Sharma unpublished results), [34]], blocks intracellular
calcium release in the parasite [35,36], which has been implicated
in RBC invasion [17–19]. In addition, cADP ribose dependent
RyR calcium channels have also been implicated in invasion [20].
Depletion of free intracellular calcium using BAPTA-AM
prevented PfGAP45 phosphorylation significantly, which was the
first indication that PfGAP45 is phosphorylated in a calcium
dependent manner in the parasite. In the same experiment, we
demonstrated that U73122 blocked its phosphorylation suggesting
that PLC mediated calcium release may be responsible for
PfGAP45 phosphorylation. The concentration of U73122 used in
these studies was 10 mM as RBC invasion is blocked at this
concentration (Vaid and Sharma, unpublished results, [18,19]. A
previous study had suggested that PfGAP45 phosphorylation may
not be dependent on calcium [20]. ProQ Diamond, a dye which is
suggested to specifically stain phosphorylated proteins, was used in
this work. We used traditional
32P labeling to detect the
phosphorylated proteins. It is possible that the significantly higher
sensitivity of
32P labeling over ProQ Diamond allowed the
detection of differences in PfGAP45 phosphorylation in these
studies. Moreover, we have used phosphorylation site specific
antibodies to confirm PfGAP45 phosphorylation. Consistent with
the earlier report [20], we did not find a significant difference in
PfGAP45 phosphorylation when parasites were treated with
Dantrolene and 8Br-cADP, which are the modulators of the
RyR pathway in this process. The phosphorylation of PfGAP45 at
S103 and S149 was almost completely abolished by BAPTA-AM
(Fig. 6). Metabolic labeling (Fig. 1, Fig. S6) indicated that even
though PfGAP45 phosphorylation was markedly reduced after
BAPTA-AM treatment, the residual phosphorylation suggested
that it may be phosphorylated at additional sites possibly in
a calcium independent manner. We identified several PfCDPK1
sites on PfGAP45 in vitro. Interestingly, S103 was phosphorylated
by both PfPKB and PfCDPK1 in vitro. To decipher, the likely
candidate kinase for this site in the parasite, A443654, which was
previously identified as a PfPKB inhibitor [17], was used. This
compound blocked the phosphorylation of S103 and not S149,
which is not a PfPKB site. Our observation that the phosphor-
ylation of S103 is mediated via the PLC-calcium pathway fits in
well with the previous finding which implicated PLC mediated
calcium release in PfPKB activation [17]. Our preliminary studies
have indicated that PLC may regulate PfCDPK1 in the parasite
(Sharma, Thomas, unpublished results), which may possibly
explain the PLC dependent phosphorylation of S149.
Our studies and those performed by Holder and co-workers
(manuscript submitted), which involved a slightly different
expression construct that had GFP between the globular domain
and the coiled-coil domain, indicated that the phosphorylation at
S89, S103 and S149 may not be essential for targeting of PfGAP45
to the IMC. However, the possibility of additional phosphorylation
at sites, other than the ones mutated in this study [30], playing
a role in this process can not be ruled out.
Despite subtle differences in the amino acid sequences of
TgGAP45 and PfGAP45 (Fig. S5), it is interesting that TgGAP45
can be replaced by PfGAP45 [13]. While the function of PfGAP45
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regulated differently in the two parasites, which may be reflected
by the differences in some of the phosphorylation sites in GAP45
from the two species. For instance, at least two of the three
phosphorylation sites identified by us (S89 and S103) are not
conserved in TgGAP45; the residue corresponding to S89 in
PfGAP45 is E117 in TgGAP45, which may mimic a phosphoser-
ine. It is possible that a negative charge may be necessary at this
position in both TgGAP45 and PfGAP45, which in the case of
PfGAP45 may be acquired as a result of phosphorylation.
However, S103 is replaced by A131 in TgGAP45, which is
a significant difference. Previously, S163 and S167 were reported
to be phosphorylated in TgGAP45 and their dephosphorylation
was considered important for interaction with TgGAP50 [15].
Although, this region of PfGAP45 and TgGAP45 is poorly
conserved, there are several threonines in this region of PfGAP45,
which may complement S163 and S167. It will be worth
investigating if these threonines undergo phosphorylation-de-
phosphorylation in the case of PfGAP45. When this manuscript
was in preparation, two proteomic studies on P. falciparum and
Toxoplasma gondii proteins were published, which included the
identification of phosphorylation sites on PfGAP45 [37] and
TgGAP45 [16]. The studies on PfGAP45 supported our present
work and suggest that S89, S103 and S149 are likely phosphor-
ylation sites on PfGAP45. Of the sites identified on TgGAP45,
only S169 and S184/185 was dependent on calcium [16]. S185 of
TgGAP45 corresponds to S149 of PfGAP45, which we have
identified as a calcium dependent phosphorylation site in
PfGAP45. Interestingly, the residue corresponding to S184 in
PfGAP45 is E148, which may mimic a phosphoserine. The
phosphorylation sites identified on TgGAP45 in this study were
mainly on the disordered region that separates coiled-coil and the
C-terminal globular domain. Our results indicate that PfGAP45 is
phosphorylated on the coiled-coil domain at S89 and S103. The
mutation of these sites did not alter the localization or interaction
of PfGAP45 with other glideosome proteins. It is possible that the
presence of endogenous PfGAP45 does not allow the effect of any
of the mutants to be dominant. Alternatively, the phosphorylation
at these sites in combination with other sites may be needed for
PfGAP45 function. Additional studies like the replacement of the
endogenous PfGAP45 allele with these phosphorylation site
mutants will be needed to address these issues.
Supporting Information
Figure S1 Generation of antisera that recognizes
PfGAP45 phosphorylated at S103 and S149. Antisera were
generated in rabbits against phosphopeptides spanning S103 and
S149 (for details see Materials and Methods). Recombinant
PfCDPK1 was incubated with recombinant PfGAP45 or its
S103A or S149A mutant in the presence or absence (negative
control) of ATP in a kinase assay mix. Subsequently, the affinity
purified antisera against phosphorylated version of S149 (a) or
S103 (b) or against the recombinant PfGAP45 (c) was used for
western blotting. Please note the mobility shift caused by the
phosphorylation of PfGAP45 in panel c.
(PDF)
Figure S2 PfGAP45 phosphorylation mutants co-localize
with endogenous PfGAP45. Immunofluorescence assays were
performed using anti-GFP (green) and anti-PfGAP45 (red)
antibodies to localize episomally expressing GAP45-GFP or its
mutants and endogenous PfGAP45.
(PDF)
Figure S3 Live Imaging of PfGAP45 phosphorylation
site mutants. A. Imaging of GFP in parasites over-expresssing
PfGAP45-GFP or its variants was performed after labeling the
nuclei with DAPI. B. Immunofluorescence assays were performed
using anti-PfMTIP (green) and anti-PfGAP45 (red) antibodies on
P. falciparum 3D7.
(PDF)
Figure S4 PfGAP45 phosphorylation site mutants asso-
ciate with the glideosome motor complex. A. Phosphory-
lation at S89, S103 and S149 does not affect PfGAP45-GFP
association with the glideosome complex. [
35S] Met/Cys was used
to metabolically label PfGAP45-GFP or mutant expressing lines at
the schizont stage. Anti GFP antibody was used to immunopre-
cipitate GAP45-GFP or its mutants. IPs were electrophoresed and
analyzed by autoradiography. The components of the motor
complex that co-immunoprecipitated are indicated based on their
molecular size [14,17]. Bottom panel, Western blot was performed
using anti-GFP antibody on the lysates used in the same IP-
experiment to assess the expression levels GAP45-GFP. B.
GAP45-GFP or its variants were immunoprecipitated from
transgenic parasite lines and the IP was used for western blotting
with anti-MTIP antibody. There was no significant difference in
the amount of MTIP co-immunoprecipitated with wild type or
mutant GAP45. Bottom panel, Western blot was performed using
MTIP antibody on the lysates used in the IP-experiment from top
panel.
(PDF)
Figure S5 Clustal W alignment of PfGAP45 and
TgGAP45 protein sequence. Cyan arrows indicate PfGAP45
phosphorylation sites identified in the present study and blue
arrows indicate the phosphorylation sites on TgGAP45 which
were identified previously [15].
(PDF)
Figure S6 PfGAP45 phosphorylation is regulated via the
PLC pathway in the parasite. [
32P] orthophosphoric acid was
used to metabolically label synchronized parasites treated with
indicated compounds as described in Fig. 1A. Immunoprecipita-
tion was carried out using anti-GAP45 antibody and the IPs were
electrophoresed and analyzed by phosphorimaging.
(PDF)
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